Nektar Therapeutics

NKTR remains in a Stage2 corrective reset with structure confirmed by a Bullish Pivot Point, supporting a medium-term bullish bias. Short-term timing is unfavorable as price is rejected at the 9EMA/20EMA and 50SMA zone. Execution posture is to stalk and await a successful pullback into the rising EMA/50SMA support area before engaging the long side.

• ↑Phase II RESPEG trials demonstrate durable and deepening responses
• ↑Ended Q1 2026 with >$1 B cash, funding Phase III development
• ↓Q1 net loss of $44.9 M far exceeds $10.5 M revenues